Tissue Regenix poised for US launch

Investors have pushed shares in Tissue Regenix (TRX) up by about 150 per cent over the past nine months in anticipation of a now imminent product launch. The medical devices company is preparing to start selling its DermaPure product - aimed at treating chronic wounds - before the end of July.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now